Compare PepsiCo, Inc. (PEP) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
PepsiCo, Inc. vs Recursion Pharmaceuticals Inc — how do they compare? PepsiCo, Inc. trades at $135.75 (market cap $184.26B), while Recursion Pharmaceuticals Inc trades at $3 (market cap $1.63B). The key difference: PepsiCo, Inc. is far larger — about 113× Recursion Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.39% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| PEP | RXRX | |
|---|---|---|
Market Cap | $184.26B | $1.63B |
Sector | Consumer Staples | Health |
52-Week High | $170.44 | $6.79 |
52-Week Low | $134.98 | $2.84 |
Enterprise Value | $226.76B | $1.05B |
Dividend Yield | 4.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PepsiCo (PEP) trades at $135.65, up 0.14% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025 with a net income margin of 10.78%, and has beaten EPS estimates in three consecutive quarters. Recent news highlights price cuts on snacks like Doritos to address consumer pushback, while analysts anticipate Q1 2026 results.
The outlook is mixed: strong profitability and dividend yield near 4% support value, but price sensitivity and debt levels pose risks. Analyst consensus is a $158.79 price target with a 'Hold' bias. Investors should weigh earnings consistency against margin pressures from recent pricing strategies.
Recursion Pharmaceuticals (RXRX) trades at $2.89, down 1.87% with a bearish technical signal despite recent earnings beats. The company shows significant revenue growth challenges with 2025 revenue of $74.26M but massive losses of -$644.76M, resulting in a -851.51% net margin. Analyst sentiment is mixed with 40% buy ratings but a consensus price target of $7.83, representing 171% upside potential from current levels.
While RXRX offers substantial upside based on analyst targets, the stock carries high risk due to persistent losses, negative cash flow from operations, and unproven AI-driven drug discovery platform. The company's heavy reliance on financing activities to fund operations presents ongoing dilution risk, making this suitable only for risk-tolerant investors betting on long-term biotech breakthroughs.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
